Compare Novavax Inc (NVAX) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs VanEck Semiconductor ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while VanEck Semiconductor ETF trades at $603.68 (market cap $73.92B). The key difference: VanEck Semiconductor ETF is far larger — about 40.6× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and VanEck Semiconductor ETF for 101 Days on average.
| NVAX | SMH | |
|---|---|---|
Market Cap | $1.82B | $73.92B |
Volume | 6,198,505 | 11,050,892 |
Sector | Health | — |
52-Week High | $12.56 | $668.91 |
52-Week Low | $6.22 | $325.10 |
Typical Hold Time | 59 Days | 101 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
SMH trades at $603.33, down 3.47% on the day, but maintains a bullish technical outlook with strong moving average support. The semiconductor ETF has delivered exceptional returns, up approximately 69% year-to-date through September 30, 2026, significantly outperforming the broader market. Recent sector strength is driven by AI demand and positive industry developments, including AMD's $8.2 billion acquisition of World Labs.
The semiconductor sector's structural growth, particularly in AI applications, supports continued upside potential. However, concentration risk in top holdings like Nvidia and sensitivity to US-China trade tensions present meaningful headwinds. Current technical levels suggest support at $597 with resistance at $620, providing clear near-term trading parameters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
